Response to the Letter to the Editor by Rob Armstrong

被引：1

作者：

Six, Robert H. ^{[1
]}

Young, David R. ^{[2
]}

Myers, Melanie R. ^{[1
]}

Mahabir, Sean P. ^{[1
]}

机构：

[1] Zoetis, Vet Med Res & Dev, 333 Portage St, Kalamazoo, MI 49007 USA

[2] YVRS, 7243 East Ave, Turlock, CA 95380 USA

来源：

PARASITES & VECTORS | 2017年 / 10卷

关键词：

AMBLYOMMA-AMERICANUM; FLURALANER; SAROLANER; DOGS;

D O I：

10.1186/s13071-017-2142-4

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ; 100103 ;

摘要：

In a recent Letter to the Editor, Armstrong raises concern that the design of the study reported by Six et al. was not consistent with the product label for treatment of Amblyomma americanum, since fluralaner was not re-administered 56 days after the initial treatment. The Authors disagree with this assessment and confirm that the design was appropriate, and therefore the results and conclusions for the entire study period are valid.

引用

页数：2

共 3 条

[1] The conclusion of a comparative efficacy study of fluralaner and sarolaner against the tick Amblyomma americanum on dogs is based on results obtained at study times that are outside the fluralaner label recommendations [J].

Armstrong, Rob .

PARASITES & VECTORS, 2017, 10

[2]

FDA FOI, 141426 NADA

[3] Comparative speed of kill of sarolaner (Simparica™ Chewables) and fluralaner (Bravecto®) against induced infestations of Amblyomma americanum on dogs [J].

Six, Robert H. ;

Young, David R. ;

Myers, Melanie R. ;

Mahabir, Sean P. .

PARASITES & VECTORS, 2016, 9

← 1 →